business

Senti Bio plans pivotal trial for AML therapy after FDA meeting

Investing.com · May 14, 2026, 12:53 PM · Also reported by 2 other sources

Read full story on Investing.com → More top stories

Also covered by

STAT News STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission Yahoo Finance SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses

Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Senti Bio plans pivotal trial for AML therapy after FDA meeting

Also covered by

More in business